Jpmorgan Chase & CO Schedule 13G passive stakes
NYSE
JPMorgan Chase & Co. has filed an amended Schedule 13G, disclosing a 1.7% beneficial ownership stake in Arcos Dorados Holdings Inc. as of May 30, 2025.
NYSE
JPMorgan Chase & Co. has filed an amended Schedule 13G, reporting a 4.2% beneficial ownership stake in AutoZone, Inc. as of May 30, 2025.
NYSE
JPMorgan Chase & Co. has filed an amended Schedule 13G, reporting a 3.9% beneficial ownership stake in D.R. Horton, Inc. as of May 30, 2025.
NYSE
JPMorgan Chase & Co. has filed an amended Schedule 13G, disclosing a beneficial ownership of 0.9% of Microchip Technology Incorporated's common stock as of May 30, 2025.
NYSE
JPMorgan Chase & Co. has filed an amended Schedule 13G, reporting a 4.4% beneficial ownership stake in Regeneron Pharmaceuticals, Inc. as of May 30, 2025.
NYSE
JPMorgan Chase & Co. has filed an amended Schedule 13G, reporting a beneficial ownership of 3.5% in Summit Hotel Properties, Inc., indicating a stake below the 5% threshold.
NYSE
SCHEDULE 13G/A: JPMorgan Chase & Co. Amends Passive Stake in Alterity Therapeutics, Reports 4.0% Ownership
JPMorgan Chase & Co. has filed an Amendment No. 1 to its Schedule 13G, disclosing a 4.0% passive beneficial ownership stake in Alterity Therapeutics Limited as of April 30, 2025.
NYSE
JPMorgan Chase & Co. has filed an amended Schedule 13G, revealing a 10.3% beneficial ownership stake in Baker Hughes Company as of April 30, 2025.
NYSE
SCHEDULE 13G/A: JPMorgan Chase & Co. Discloses 2.9% Passive Stake in IBEX LIMITED via Amended Schedule 13G Filing
JPMorgan Chase & Co. has filed an amended Schedule 13G, disclosing a 2.9% beneficial ownership stake in IBEX LIMITED as of April 30, 2025.
NYSE
SCHEDULE 13G/A: JPMorgan Chase & Co. Discloses 0.2% Beneficial Ownership in Keros Therapeutics, Inc.
JPMorgan Chase & Co. has filed an amended Schedule 13G, reporting a 0.2% beneficial ownership stake in Keros Therapeutics, Inc. as of April 30, 2025.
NYSE
SCHEDULE 13G/A: JPMorgan Chase & Co. Discloses 10.1% Passive Stake in Seagate Technology Holdings PLC
JPMorgan Chase & Co. has reported a 10.1% beneficial ownership stake in Seagate Technology Holdings PLC, held for investment purposes in the ordinary course of business.
NYSE
JPMorgan Chase & Co. has disclosed a 6.3% passive beneficial ownership stake in Alterity Therapeutics Limited, as reported in a recent Schedule 13G filing.
NYSE
JPMorgan Chase & Co. has filed a Schedule 13G, revealing a 6.3% beneficial ownership stake in Keros Therapeutics, Inc. as of March 31, 2025.
NYSE
JPMorgan Chase & Co. has reported a 5.1% beneficial ownership stake in IBEX LIMITED, primarily through its banking and investment management subsidiaries.
NYSE
JPMorgan Chase & Co. has filed a Schedule 13G, reporting beneficial ownership of 5.0% of McDonald's Corporation's common stock as of March 31, 2025.
NYSE
JPMorgan Chase & Co. has reported a 6.4% beneficial ownership stake in Oscar Health, Inc.'s Class A Common Stock as of March 31, 2025, filed under SEC Rule 13d-1(b).
NYSE
JPMorgan Chase & Co. has filed a Schedule 13G, revealing a 5.5% beneficial ownership stake in SBA Communications Corporation's Class A Common Stock as a passive investor.
NYSE
JPMorgan Chase & Co. has filed a Schedule 13G, revealing a beneficial ownership of 6.2% of Twilio Inc.'s Class A Common Stock as of March 31, 2025.
NYSE
JPMorgan Chase & Co. has reported a 5.1% beneficial ownership stake in Vulcan Materials Company, held for ordinary course of business purposes.
NYSE
JPMorgan Chase & Co. has filed a Schedule 13G, reporting a 6.2% beneficial ownership stake in Yum China Holdings, Inc. as of March 31, 2025, indicating a passive investment.
NYSE
JPMorgan Chase & Co. has filed a Schedule 13G, reporting a 6.0% beneficial ownership stake in Ameriprise Financial, Inc. as of March 31, 2025.
NYSE
JPMorgan Chase & Co. has filed a Schedule 13G, revealing a beneficial ownership of 5.1% in Bristol-Myers Squibb Company as of March 31, 2025.
NYSE
JPMorgan Chase & Co. has filed a Schedule 13G, revealing a beneficial ownership of 6.1% in Cartesian Therapeutics, Inc.'s common stock as of March 31, 2025.
NYSE
JPMorgan Chase & Co. has filed a Schedule 13G, revealing a beneficial ownership of 5.4% of Eaton Corporation plc's ordinary shares as of March 31, 2025.
NYSE
JPMorgan Chase & Co. has filed a Schedule 13G, reporting a 5.8% beneficial ownership stake in Flowco Holdings Inc.'s Class A common stock as of March 31, 2025.
NYSE
JPMorgan Chase & Co. has filed a Schedule 13G, reporting a passive beneficial ownership of 5.0% in Henry Schein, Inc.'s common stock as of March 31, 2025.
NYSE
JPMorgan Chase & Co. has filed a Schedule 13G, revealing a beneficial ownership of 5.9% of Howmet Aerospace Inc.'s common stock as of March 31, 2025.
NYSE
JPMorgan Chase & Co. has filed an amendment to its Schedule 13G, reporting a beneficial ownership of 6.7% in Arthur J. Gallagher & Co. as of March 31, 2025.
NYSE
SCHEDULE 13G/A: JPMorgan Chase & Co. Files Amendment No. 4, Disclosing 9.3% Stake in Baker Hughes Company
JPMorgan Chase & Co. has filed its fourth amendment to Schedule 13G, revealing a beneficial ownership of 9.3% of Baker Hughes Company's Class A Common Stock as of March 31, 2025.
NYSE
JPMorgan Chase & Co. has filed an amended Schedule 13G, reporting a 7.6% beneficial ownership stake in Bright Horizons Family Solutions Inc. as of March 31, 2025.